Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
FDMT vs BEAM: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FDMT Captures Overall Composite Edge (42.1 HOLD vs 45.9 HOLD), While BEAM Leads 3–2 on Growth & Valuation Pillars
FDMT Overall Winner
6-Pillar Tally: FDMT 2 – 3 BEAM (1 Tie)
Matrix Metrics: FDMT 3 – 5 BEAM
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (42.1/100 HOLD vs. 45.9/100 HOLD) after splitting the core matrix 3–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus BEAM at $21.29 (N/M Forward P/E, -267.7% operating margin).
- Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -267.7% operating margin) and revenue trajectory (+4505.6% vs. -96.8% YoY).
- Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About FDMT vs BEAM
FDMT
Head-to-Head Winner
4D Molecular Therapeutics, Inc. Common Stock
$11.65
-4.74% 1D
Market Cap
$669.3M
TTM Revenue
$96M
Forward P/E
N/M
Beta / 30D Vol
1.89β · 90% Vol
Unified Composite Score
42.1
HOLD
Tech 21.0
Fund 54.0
Flow 66.0
Mom 54.0
Weinstein Technical Phase
Neutral · Hold
BEAM
Beam Therapeutics Inc. Common Stock
$21.29
-6.75% 1D
Market Cap
$2.4B
TTM Revenue
$147M
Forward P/E
N/M
Beta / 30D Vol
2.24β · 86% Vol
Unified Composite Score
45.9
HOLD
Tech 30.0
Fund 52.0
Flow 70.0
Mom 70.0
Weinstein Technical Phase
Markdown · Sell / avoid
6-Pillar Scorecard Institutional Category Breakdown (FDMT 2 – 3 BEAM)
1. Valuation Multiples
FDMT
Forward P/E
N/M
N/M
Trailing P/E
N/M
N/M
PEG Ratio
N/M
N/M
EV / Revenue
6.6x
16.8x
2. Growth & Scale
BEAM
Revenue Growth (YoY)
+4505.6%
-96.8%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
$96M
$147M
Market Cap
$669.3M
$2.4B
3. Profitability & Quality
BEAM
Gross Margin
N/A
N/A
Operating Margin
-222.7%
-267.7%
Net Profit Margin
-208.6%
-73.9%
Return on Equity (ROE)
-56.7%
-11.3%
4. Balance Sheet & Cash Flow
FDMT
Cash Generation (TTM)
-$156M
-$398M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$31M Net Cash
$31M Net Debt (0.26x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
BEAM
Options Structure Phase
BREAKDOWN
BREAKDOWN
Current IV / %ile
82.4% (10th %ile)
66.0% (42nd %ile)
Put/Call OI Skew
5.16x (Put-Skewed)
0.47x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: FDMT (3) vs BEAM (5)| Institutional Metric | FDMT | BEAM | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $669.3M | $2.4B | BEAM | |
| Trailing P/E Ratio | N/M | N/M | Tie | |
| Forward P/E Ratio | N/M | N/M | Tie | |
| Revenue Growth (YoY) | +4505.6% | -96.8% | FDMT | |
| Operating Margin (TTM) | -222.7% | -267.7% | FDMT | |
| Net Profit Margin | -208.6% | -73.9% | BEAM | |
| Return on Equity (ROE) | -56.7% | -11.3% | BEAM | |
| 52-Week Range Position | 47% ($7–$17) | 6% ($20–$38) | FDMT | |
| Beta / 30D Volatility | 1.89β · 90% Vol | 2.24β · 86% Vol | BEAM | |
| Unified Institutional Score | 42.1 / 100 (HOLD) | 45.9 / 100 (HOLD) | BEAM | |
| Trailing 12M Revenue (USD) | $96M | $147M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · 6.6x EV/Rev | N/M PEG · 16.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$156M ($31M Net Cash) | -$398M ($31M Net Debt (0.26x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
FDMT +5.25 pp
3M Horizon
BEAM +0.99 pp
6M Horizon
FDMT +59.86 pp
1Y Horizon
FDMT +15.04 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | FDMT Revenue | BEAM Revenue | FDMT Op. Margin | BEAM Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $10M | $0M | -729.4% | -417522.2% | FDMT |
| FY2020 | $10M | $0M | -424.0% | -553166.7% | FDMT |
| FY2021 | $20M | $50M | -395.5% | -757.0% | FDMT |
| FY2022 | $0M | $60M | -3516.5% | -555.6% | BEAM |
| FY2023 | $20M | $380M | -544.6% | -46.7% | BEAM |
| FY2024 | $0M | $60M | -507678.4% | -654.3% | BEAM |
| FY2025 | $90M | $140M | -187.2% | -274.6% | FDMT |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
FDMT
BREAKDOWN
Current IV
82.4%
IV Percentile
10th %ile
Put/Call OI Skew
5.16x (Put-Skewed)
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact FDMT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
BEAM
BREAKDOWN
Current IV
66.0%
IV Percentile
42nd %ile
Put/Call OI Skew
0.47x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
DISTRIBUTION
Exact BEAM Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
FDMT Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
BEAM Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ FDMT vs BEAM Key Questions & Quantitative Answers
As of Nov 16, 2026, 4D Molecular Therapeutics, Inc. (FDMT) captures the overall head-to-head institutional edge over Beam Therapeutics Inc. (BEAM) on higher Unified Composite conviction (42.1/100 HOLD vs. 45.9/100 HOLD) after splitting the core matrix 3–5 (led by Valuation Multiples, Balance Sheet & Cash Flow), while BEAM wins 3–2 across the 6-pillar growth and valuation breakdown. FDMT trades at $11.65 (N/M Forward P/E, -222.7% operating margin) versus BEAM at $21.29 (N/M Forward P/E, -267.7% operating margin). Composite vs. Pillar Nuance: While BEAM currently prints a higher short-term Unified Composite Score (45.9/100 HOLD vs. FDMT 42.1/100 HOLD), FDMT captures the overall institutional head-to-head verdict (3–5 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (-222.7% vs. -267.7% operating margin) and revenue trajectory (+4505.6% vs. -96.8% YoY). Technical & Structure Timing Caution: FDMT is currently in a Breakdown options structure phase (RSI 46.9); meanwhile BEAM is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 37.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
BEAM leads the Growth & Scale pillar: FDMT posts +4505.6% YoY revenue growth and +0.0% YoY earnings growth on $96M TTM revenue (N/A gross margin, -222.7% operating margin), compared with BEAM at -96.8% YoY revenue growth and +0.0% YoY earnings growth on $147M TTM revenue (N/A gross margin, -267.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), FDMT cumulative revenue shifted +800.0% while BEAM shifted +180.0%. In operating R&D and SG&A reinvestment, FDMT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for BEAM.
FDMT screens cheaper on headline valuation multiples. FDMT trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.6x EV/Revenue (unreported FCF margin), whereas BEAM trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 16.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against FDMT (-56.7% ROE) versus BEAM (-11.3% ROE) capital efficiency.
In options market volatility and institutional positioning, FDMT carries 82.4% implied volatility (10th %ile, Compressed (<25th %ile)), a 5.16x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (1.89β · 90% Vol realized risk). By comparison, BEAM carries 66.0% implied volatility (42nd %ile, Balanced (25th–60th %ile)), a 0.47x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.24β · 86% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
BEAM vs FDMT · Reverse Pair
FDMT vs STOK
· Sector Peer
FDMT vs ANNX
· Sector Peer
FDMT vs CGEM
· Sector Peer
BEAM vs NTLA
· Sector Peer
BEAM vs TWST
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem